63 is the total number of securities Sarissa Capital Management LP has owned. The longest Sarissa Capital Management LP has owned a single stock is 32 quarters.
| Period | Weighting | Quarter | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
| BIIB | BIOGEN INC. | 32 | 32 | 12.80% | 22.20% | 37.10% | Q4 2015 | Q3 2023 | 32 |
| INVA | INNOVIVA INC. | 29 | 29 | 2.53% | 10.88% | 19.53% | Q3 2016 | Q3 2023 | 29 |
| IRWD | IRONWOOD PHARMACEUTICA... | 24 | 24 | 6.33% | 16.05% | 24.17% | Q4 2017 | Q3 2023 | 24 |
| ABBV | ABBVIE INC. | 22 | 1 | 0.01% | 4.97% | 24.43% | Q4 2013 | Q2 2020 | 23 |
| MDCO | MEDICINES CO. | 20 | 20 | 7.18% | 16.80% | 33.86% | Q1 2015 | Q4 2019 | 20 |
| MRSN | MERSANA THERAPEUTICS INC. | 19 | 19 | 0.09% | 3.13% | 7.95% | Q1 2019 | Q3 2023 | 19 |
| ALKS | ALKERMES PLC | 16 | 16 | 6.44% | 25.54% | 43.75% | Q4 2019 | Q3 2023 | 16 |
| ICPT | INTERCEPT PHARMACEUTIC... | 15 | 15 | 0.00% | 5.41% | 10.69% | Q4 2017 | Q2 2021 | 15 |
| BCRX | BIOCRYST PHARMACEUTICA... | 14 | 14 | 0.54% | 2.85% | 7.44% | Q2 2020 | Q3 2023 | 14 |
| VVUS | VIVUS INC | 14 | 14 | 0.51% | 2.40% | 8.75% | Q4 2013 | Q1 2017 | 14 |
| AVEO | AVEO PHARMACEUTICALS INC | 14 | 14 | 0.24% | 0.82% | 1.77% | Q4 2013 | Q1 2017 | 14 |
| ARIA | ARIAD PHARMACEUTICALS INC | 13 | 13 | 15.61% | 27.58% | 44.03% | Q4 2013 | Q4 2016 | 13 |
| ITCI | INTRA CELLULAR THERAPI... | 13 | 13 | 0.79% | 3.21% | 7.44% | Q1 2014 | Q1 2017 | 13 |
| DGX | QUEST DIAGNOSTICS INC | 12 | 12 | 0.97% | 11.17% | 18.40% | Q4 2013 | Q3 2016 | 12 |
| RGLS | REGULUS THERAPEUTICS INC. | 12 | 12 | 0.05% | 0.15% | 0.29% | Q2 2019 | Q1 2022 | 12 |
| GILD | GILEAD SCIENCES INC | 11 | 11 | 7.06% | 11.66% | 18.16% | Q1 2021 | Q3 2023 | 11 |
| VOR | VOR BIOPHARMA INC | 11 | 11 | 0.18% | 0.71% | 2.92% | Q1 2021 | Q3 2023 | 11 |
| MRTX | MIRATI THERAPEUTICS INC. | 11 | 11 | 0.01% | 0.01% | 0.02% | Q4 2018 | Q2 2021 | 11 |
| AGN | ALLERGAN PLC | 10 | 10 | 7.42% | 14.72% | 21.99% | Q4 2017 | Q1 2020 | 10 |
| JAZZ | JAZZ PHARMACEUTICALS PLC | 10 | 10 | 0.01% | 6.74% | 15.63% | Q1 2019 | Q2 2021 | 10 |
| RPRX | REPROS THERAPEUTICS INC | 10 | 10 | 0.21% | 2.72% | 5.90% | Q4 2013 | Q1 2016 | 10 |
| AMRN | AMARIN CORP PLC | 9 | 9 | 0.58% | 2.95% | 7.46% | Q3 2021 | Q3 2023 | 9 |
| MRK | MERCK & CO INC NEW | 8 | 8 | 4.85% | 6.92% | 9.16% | Q4 2013 | Q3 2015 | 8 |
| NVLNF | NOVELION THERAPEUTICS ... | 8 | 8 | 0.67% | 1.90% | 4.35% | Q4 2016 | Q3 2018 | 8 |
| APRI | APRICUS BIOSCIENCES INC | 8 | 8 | 0.36% | 1.72% | 2.57% | Q4 2014 | Q3 2016 | 8 |
| AMGN | AMGEN INC | 7 | 7 | 1.81% | 7.14% | 17.93% | Q2 2014 | Q4 2015 | 7 |
| AEGR | AEGERION PHARMACEUTICA... | 7 | 7 | 1.12% | 5.23% | 9.04% | Q1 2015 | Q3 2016 | 7 |
| KIN | KINDRED BIOSCIENCES INC | 7 | 7 | 0.65% | 1.19% | 1.82% | Q1 2014 | Q3 2015 | 7 |
| APRI | APRICUS BIOSCIENCES INC. | 7 | 7 | 0.11% | 0.57% | 1.21% | Q4 2016 | Q2 2018 | 7 |
| ALXN | ALEXION PHARMACEUTICAL... | 6 | 6 | 1.55% | 8.89% | 12.72% | Q1 2020 | Q2 2021 | 6 |
| ADXS | ADVAXIS INC | 6 | 6 | 0.44% | 1.02% | 1.48% | Q2 2016 | Q3 2017 | 6 |
| TRGT | TARGACEPT INC | 6 | 6 | 0.40% | 0.58% | 0.97% | Q1 2014 | Q2 2015 | 6 |
| PEAR THERAPEUTICS INC | 6 | 6 | 0.02% | 0.13% | 0.27% | Q4 2021 | Q1 2023 | 6 | |
| REGULUS THERAPEUTICS INC | 6 | 6 | 0.02% | 0.03% | 0.04% | Q2 2022 | Q3 2023 | 6 | |
| BRLI | BIO-REFERENCE LABS INC | 5 | 5 | 2.73% | 9.28% | 13.88% | Q4 2013 | Q4 2014 | 5 |
| PCRX | PACIRA PHARMACEUTICALS... | 5 | 5 | 3.39% | 5.53% | 7.94% | Q3 2015 | Q3 2016 | 5 |
| ANIP | ANI PHARMACEUTICALS INC | 5 | 5 | 0.27% | 0.41% | 0.62% | Q4 2014 | Q4 2015 | 5 |
| SHPG | SHIRE PLC | 4 | 4 | 0.04% | 4.92% | 10.46% | Q1 2018 | Q4 2018 | 4 |
| PBYI | PUMA BIOTECHNOLOGY INC. | 4 | 4 | 1.91% | 4.62% | 8.28% | Q4 2018 | Q3 2019 | 4 |
| ARRY | ARRAY BIOPHARMA INC | 4 | 4 | 0.57% | 3.37% | 6.68% | Q4 2015 | Q3 2016 | 4 |
| EBIO | ELEVEN BIOTHERAPEUTICS... | 4 | 4 | 0.02% | 0.08% | 0.17% | Q4 2014 | Q3 2015 | 4 |
| IDIX | IDENIX PHARMACEUTICALS... | 3 | 3 | 10.48% | 12.73% | 16.39% | Q4 2013 | Q2 2014 | 3 |
| ESPR | ESPERION THERAPEUTICS ... | 3 | 3 | 1.94% | 2.30% | 2.61% | Q3 2015 | Q1 2016 | 3 |
| ACHN | ACHILLION PHARMACEUTIC... | 3 | 3 | 0.43% | 1.74% | 2.96% | Q3 2017 | Q1 2018 | 3 |
| ENTA | ENANTA PHARMACEUTICALS... | 3 | 3 | 0.69% | 1.28% | 1.60% | Q1 2014 | Q3 2014 | 3 |
| ONTX | ONCONOVA THERAPEUTICS INC | 3 | 3 | 0.58% | 0.66% | 0.76% | Q1 2014 | Q3 2014 | 3 |
| SRSAW | SARISSA CAPITAL ACQUIS... | 3 | 3 | 0.40% | 0.46% | 0.51% | Q4 2020 | Q2 2021 | 3 |
| BIOVERATIV INC | 2 | 2 | 20.52% | 21.96% | 23.40% | Q2 2017 | Q3 2017 | 2 | |
| BIVV | BIOVERATIV INC | 1 | 1 | 3.34% | 9.71% | 16.08% | Q1 2017 | Q4 2017 | 2 |
| A | AGILENT TECHNOLOGIES INC. | 2 | 2 | 6.66% | 8.39% | 10.12% | Q3 2014 | Q4 2014 | 2 |
| MNKKQ | MALLINCKRODT PUB LTD CO | 2 | 2 | 5.48% | 5.74% | 6.00% | Q4 2013 | Q1 2014 | 2 |
| NBIX | NEUROCRINE BIOSCIENCES... | 2 | 2 | 2.17% | 3.86% | 5.55% | Q2 2023 | Q3 2023 | 2 |
| RPTP | RAPTOR PHARMACEUTICAL ... | 2 | 2 | 2.76% | 3.57% | 4.38% | Q1 2016 | Q2 2016 | 2 |
| LH | LABORATORY CORP AMER H... | 2 | 2 | 1.28% | 1.30% | 1.32% | Q1 2014 | Q2 2014 | 2 |
| TARGACEPT INC | 2 | 2 | 0.13% | 0.14% | 0.15% | Q4 2015 | Q1 2016 | 2 | |
| MEDICINES CO | 1 | 1 | 5.68% | 5.68% | 5.68% | Q4 2019 | Q4 2019 | 1 | |
| BMY | BRISTOL MYERS SQUIBB CO | 1 | 1 | 4.98% | 4.98% | 4.98% | Q4 2013 | Q4 2013 | 1 |
| PFE | PFIZER INC | 1 | 1 | 4.70% | 4.70% | 4.70% | Q4 2013 | Q4 2013 | 1 |
| FLML | FLAMEL TECHNOLOGIES SA | 1 | 1 | 3.32% | 3.32% | 3.32% | Q1 2015 | Q1 2015 | 1 |
| PRGO | PERRIGO CO PLC | 1 | 1 | 2.57% | 2.57% | 2.57% | Q2 2016 | Q2 2016 | 1 |
| CYCN | CYCLERION THERAPEUTICS... | 1 | 1 | 0.36% | 0.36% | 0.36% | Q2 2019 | Q2 2019 | 1 |
| CBIO | CATALYST BIOSCIENCES INC. | 1 | 1 | 0.10% | 0.10% | 0.10% | Q3 2015 | Q3 2015 | 1 |
| CYCC | CYCLACEL PHARMACEUTICA... | 1 | 1 | 0.09% | 0.09% | 0.09% | Q4 2014 | Q4 2014 | 1 |
Download | |||||||||
The securities at the top of the list , including BIOGEN INC., INNOVIVA INC., and IRONWOOD PHARMACEUTICALS INC., are the highest-conviction holdings of Sarissa Capital Management LP.
The conviction is calculated by counting the number of quarters a security has been reported by Sarissa Capital Management LP. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Sarissa Capital Management LP owns currently or has owned in the past.